Company Overview

Delcath Systems, Inc. is a U.S.-based interventional oncology company focused on the treatment of primary and metastatic cancers of the liver. The company develops and commercializes targeted regional therapies designed to deliver high-dose chemotherapy directly to the liver while limiting systemic exposure. Delcath operates primarily within the oncology medical device and specialty pharmaceutical sectors, with its commercial and clinical efforts centered on hepatic-directed cancer therapies.

The company’s principal product platform is the HEPZATO KIT, a combination drug-device product used in hepatic delivery of melphalan through a proprietary percutaneous hepatic perfusion (PHP) system. Revenue generation is primarily tied to commercialization of the therapy in the United States and related clinical adoption activities. Delcath has historically focused on metastatic uveal melanoma and other unresectable hepatic-dominant malignancies. The company was founded in 1988 and evolved from a development-stage medical technology company into a commercial-stage oncology company following U.S. regulatory approvals and expanded commercialization efforts.

Business Operations

Delcath’s operations are centered around the commercialization and clinical support of its proprietary PHP platform. The company’s core business includes sales of the HEPZATO KIT in the United States and support for related treatment procedures at specialized cancer centers. The platform combines a drug component, melphalan hydrochloride, with a proprietary delivery and filtration system intended to isolate hepatic circulation during treatment. Delcath’s business model depends on hospital adoption, physician training, reimbursement coverage, and ongoing clinical evidence generation.

Internationally, Delcath has historically maintained a presence in Europe through commercialization and distribution activities involving its hepatic perfusion technology under earlier CE Mark authorizations. Operations have included relationships with treatment centers and distributors in select international markets, though the company’s primary commercial focus has shifted toward the U.S. market following FDA approval milestones. Delcath controls intellectual property associated with its PHP technology platform and relies on specialized manufacturing, clinical operations, and regulatory infrastructure to support commercialization and post-market activities.

Strategic Position & Investments

Delcath’s strategic direction is focused on expanding adoption of hepatic-directed therapies in oncology and increasing utilization of the HEPZATO KIT across eligible patient populations. The company has emphasized physician education, treatment center expansion, reimbursement support, and post-approval clinical data generation as key growth initiatives. Delcath has also pursued broader awareness within the oncology community regarding treatment options for metastatic uveal melanoma with liver involvement, an area with historically limited therapeutic alternatives.

The company continues to invest in clinical development activities evaluating the potential application of its PHP system in additional hepatic malignancies beyond uveal melanoma metastases. Strategic priorities include strengthening commercial infrastructure, expanding treatment site networks, and advancing evidence supporting the safety and efficacy of regional chemotherapy delivery. Public filings and investor communications indicate continued focus on operational scaling rather than diversification into unrelated therapeutic categories. Data regarding material joint ventures or large-scale acquisition activity remains limited based on available public disclosures.

Geographic Footprint

Delcath is headquartered in New York, United States, and its primary commercial operations are concentrated in the United States. The company markets the HEPZATO KIT domestically through relationships with cancer centers and healthcare institutions capable of performing PHP procedures. Its U.S. activities represent the central driver of current commercial strategy and revenue generation.

Outside the United States, Delcath has maintained historical operational and regulatory engagement in parts of Europe, particularly through prior CE Mark-related commercialization activities. The company’s international footprint is comparatively smaller than its domestic operations, though it continues to monitor opportunities for broader geographic expansion where regulatory and reimbursement conditions support adoption of hepatic perfusion technologies.

Leadership & Governance

Delcath is led by an executive team with experience in oncology commercialization, medical devices, specialty pharmaceuticals, and healthcare operations. Corporate governance is overseen by a board of directors responsible for strategic direction, regulatory oversight, and capital allocation. The company’s leadership strategy has emphasized commercialization execution, clinical validation, and disciplined expansion within targeted oncology markets.

Key executives include:

• Gerard Michel – President and Chief Executive Officer
• David McDonald – Chief Financial Officer
• Andrew McDonald – Executive Vice President, Operations
• Stephen Isaacs – Executive Vice President, General Counsel and Secretary

Leadership communications in public filings and investor materials have consistently highlighted a strategy centered on expanding access to hepatic-directed oncology therapies, supporting treatment-center adoption, and advancing Delcath’s proprietary PHP platform within interventional oncology markets.